| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 28th December 2020 | Stephen Connelly | 25,000 | Open or private sale | $4.52 | $113,045.00 |
| 23rd December 2020 | Jason A Keyes | 8,000 | Open or private sale | $4.74 | $37,913.60 |
| 28th September 2020 | Stephen Connelly | 25,000 | Open or private sale | $5.62 | $140,395.00 |
| 13th July 2020 | Stephen Connelly | 250,000 | Open or private sale | $8.13 | $2,033,475.00 |
| 10th June 2020 | Jason A Keyes | 5,014 | Other acquisition or disposition | $2.41 | $12,083.74 |
| 10th June 2020 | Christine Zedelmayer | 9,570 | Other acquisition or disposition | $2.41 | $23,063.70 |
| 18th February 2020 | Jason A Keyes | 5,000 | Open or private sale | $5.03 | $25,137.50 |
| 21st January 2020 | Jason A Keyes | 5,000 | Open or private sale | $4.41 | $22,043.00 |
| 3rd September 2019 | Jason A Keyes | 5,000 | Open or private sale | $3.60 | $17,980.50 |
| 1st August 2019 | Jason A Keyes | 5,000 | Open or private sale | $3.99 | $19,941.00 |
Equillium
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Equillium, Inc. is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.
Ticker: EQ
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1746466
Employees: 16
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
News
Equillium (EQ) Investor Presentation - Slideshow
4th December 2020
Equillium to Host Virtual Investor and Analyst Day on December 4, 2020
30th November 2020
Equillium Provides Itolizumab COVID-19 Program Update
25th November 2020